medigraphic.com

2016, Number 2

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2016; 54 (2)

Allopurinol hypersensitivity syndrome. A report of two cases

Rodríguez-Arámbula A, Arenas-Velázquez E, Castanedo-Cázares JP, Hernández-Blanco D, Oros-Ovalle C, Torres-Álvareza B

Language: Spanish
References: 9
Page: 261-264
PDF size: 241.31 Kb.


ABSTRACT

Patients in treatment with allopurinol are in risk of having life threatening adverse reactions particularly at the beginning of the treatment. Two percent of the patients prescribed with this drug have associated severe cutaneous adverse reactions. We present two cases of allopurinol hypersensitivity syndrome in mexican patients in which asymptomatic hyperuricemia was the indication to its use. The general physician and the specialist must be alert of this syndrome that causes elevate morbidity and mortality.


REFERENCES

  1. Stamp L, O’Donnell J, Chapman J. Emerging therapies in the long-term management of hyperuricaemia and gout. Intern Med J. 2007;37:258–266.

  2. Lee HY, Pang SM, Thamotharampillai T. Allopurinol induced Stevens-Johnson syndrome and Toxic Epidermal Necrolysis. J Am Acad Dermatol. 2008;59:352-3.

  3. Zineh I, Mummaneni P, Lyndly J, Amur S, La Grenade LA, Chang SH, et al. Allopurinol pharmacogenetics: assessment of potential clinical usefulness. Pharmacogenomics. 2011;12:1741-9.

  4. Lee HY, Ariyasinghe JT, Thirumoorthy T. Allopurinol hypersensitivity syndrome: A preventable severe cutaneous adverse reaction. Singapore Med J. 2008; 49:384-7.

  5. Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum. 1986;29:82-7.

  6. Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58:25-32.

  7. Eshki M, Allanore L, Musette P, Milpied B, Grange A, Guillaume JC, et al. Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 2009;145:67-72

  8. Hernández A, Ponce de León S, Rangel S, Criollo E, Archer C, Orozco R. Epidemiology of adverse cutaneous drugs reactions. A prospective study in hospitalized patients. Arch Med Res. 2006; 37:899-902.

  9. Hernández Salazar A, Vega Memije E, Hojyo Tomoka MT. Epidemiología de las reacciones cutáneas adversas a fármacos, en el Servicio de Dermatología del Hospital General Dr. Manuel Gea González. Dermatología Rev Mex 2011;55 (6):327-333




2020     |     www.medigraphic.com